Hepatitis C

Publisher Website
Google Scholar
Abstract
Recombinant DNA technology has brought us to a new era in research on and control of non-A, non-B hepatitis. The cloning and sequencing of what is being called hepatitis C virus1 and the development of a serologic assay to detect antibody to a part (epitope) of this virus (anti-HCV)2 have been major break-throughs in the long search for a causative agent of non-A, non-B hepatitis. These developments provide an opportunity to redefine and expand our knowledge of the epidemiology and natural history of the disease, to determine more accurately the amount of acute and chronic disease, and to evaluate preventive . . .